0 0 -0.00153711605226205 -0.00377653512840222 -0.00817586727797958 -0.00796385127077093 -0.00962685182731309 -0.0113163543847561
Sign Up Today X
Thanks for submitting the form.
Stockreport

Vyriad signs 'huge' deal with Novartis to develop new cancer treatments [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
"It's huge. We are so delighted because it gives us financial security stretching significantly into the future," Vyriad CEO and Co-founder Dr. Stephen Russell. "And this endorses this new technology that we've developed. ... We've got this external endorsement of our technology platform by a leading company in this area. They're the Rolls Royce engine. This will drive this technology to the first in-human clinical testing." Vyriad and its sister company, Imanis Life Sciences, develop cancer therapies by genetically tailoring viruses to turn a patient's own T cells into "serial killers" to attack and destroy cancer. CAR-T therapies have become a more common method as a way to treat cancer in recent years. However, it is expensive and time consuming as the current approach is to remove cells from a patient, ship them to a lab to be genetically altered and then sent back to be infused back into the patient. The new collaboration between Vyriad and Novartis is based around Vyriad' [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

Vyriad signs 'huge' deal with Novartis to develop new cancer treatments [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
"It's huge. We are so delighted because it gives us financial security stretching significantly into the future," Vyriad CEO and Co-founder Dr. Stephen Russell. "And this endorses this new technology that we've developed. ... We've got this external endorsement of our technology platform by a leading company in this area. They're the Rolls Royce engine. This will drive this technology to the first in-human clinical testing." Vyriad and its sister company, Imanis Life Sciences, develop cancer therapies by genetically tailoring viruses to turn a patient's own T cells into "serial killers" to attack and destroy cancer. CAR-T therapies have become a more common method as a way to treat cancer in recent years. However, it is expensive and time consuming as the current approach is to remove cells from a patient, ship them to a lab to be genetically altered and then sent back to be infused back into the patient. The new collaboration between Vyriad and Novartis is based around Vyriad' [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS